Eton Pharmaceuticals Starts New Program to Evaluate Mecasermin in Treating Spasms

07:19 AM EST, 11/02/2026 (MT Newswires) -- Eton Pharmaceuticals (ETON) launched ET-900, a new development program evaluating mecasermin injection as a treatment for infantile and epileptic spasms, the company said Monday. The company also signed a license deal with Baylor College of Medicine for the use of insulin-like growth factor1, or IGF-1, for spasm treatment, it said. Financial details weren't disclosed. Mecasermin is a "recombinant form" of IGF-1, the company said. Eton has submitted an investigational new drug application to the US Food and Drug Administration for a phase 2 study to evaluate mecasermin/IGF-1 in children with refractory epileptic spasms, with initial enrollment and dosing expected in Q1 2027, the company said.